Home / Market News / $NIKI

$NIKI news and market catalysts

The 8 most recent market catalysts affecting $NIKI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 0 high impact 4 bullish 1 bearish Biotechnology
Oct 28, 2026 Corporate Catalyst Bullish Impact 55
Niki BioSolutions Subsidiary DiamiR Biosciences Receives NYSDOH Approval for Expanded APOE Genotyping Specimen Types
Niki BioSolutions' subsidiary, DiamiR Biosciences, secured NYSDOH approval to expand the types of specimens that can be used for its APOE Genotyping test. This is significant becau…
Oct 24, 2026 Corporate Catalyst Bullish Impact 55
Niki BioSolutions Subsidiary DiamiR Biosciences Signs APOE Genotyping Agreement with Charter Research
Niki BioSolutions announced that its subsidiary, DiamiR Biosciences, has signed an agreement with Charter Research to perform APOE genotyping. This is a positive development for Ni…
Oct 14, 2026 Corporate Catalyst Neutral Impact 55
Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group
Niki BioSolutions announced that its subsidiary, DiamiR Biosciences, will conduct APOE genotyping for the Global Alzheimer’s Platform Foundation’s Bio-Hermes-002 study. This is sig…
Oct 9, 2026 Corporate Catalyst Neutral Impact 55
Niki BioSolutions Enters At The Market Offering Agreement On October 9, 2026; May Sell Common Stock Up To $1.40M Aggregate Maximum Offering Price
Niki BioSolutions has established an At-The-Market (ATM) offering facility, enabling them to sell up to $1.4 million worth of common stock into the open market. This is a common me…
Sep 14, 2026 Corporate Catalyst Neutral Impact 65
Niki BioSolutions' DiamiR Announces Engagement Of Fios Genomics For Bioinformatics And Biostatistics Analysis Supporting Alzheimer's Disease Program; Terms Not Disclosed
This announcement is a positive development for Niki BioSolutions (NIKI) as it indicates tangible progress in their Alzheimer's disease program. Engaging a specialized firm like Fi…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
Niki BioSolutions shares are trading higher after the company announced its subsidiary, DiamiR Biosciences, entered into agreement to provide Progressive Medical Research with Apolipoprotein E genotyping services.
This headline indicates a positive development for Niki BioSolutions, as its subsidiary DiamiR Biosciences has secured a new agreement. This provides a clear revenue stream and val…
Jul 23, 2026 Corporate Catalyst Bullish Impact 55
Niki BioSolutions’ DiamiR Biosciences Agrees To Provide Progressive Medical Research With Apolipoprotein E Genotyping Services In Support Of Ongoing Clinical And Translational Research Programs
Niki BioSolutions' wholly-owned subsidiary, DiamiR Biosciences, has secured an agreement to provide Apolipoprotein E (APOE) genotyping services to Progressive Medical Research (PMR…
Jul 21, 2026 Corporate Catalyst Bearish Impact 75
Niki BioSolutions Shares Halted On Circuit Breaker To The Upside, Stock Now Up 13.36%
The circuit breaker halt to the upside for Niki BioSolutions signifies a sudden and substantial positive price movement, likely triggered by a significant corporate event such as a…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.